LSDPsilocybin

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

We don't know much about the effects of microdosing or have even defined it rigorously. Kuypers and colleagues (2019) ask the questions and take the first step in building a framework for a more scientific microdosing study. Microdosing is defined as the 1) use of a low dose below the perceptual threshold that does not impair ‘normal’ functioning of an individual, 2) a procedure that includes multiple dosing sessions, and 3) with the intention to improve well-being and enhance cognitive and emotional processes.

Authors

  • Gitte Knudsen

Published

Journal of Psychopharmacology
meta Study

Abstract

Background: In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing is.Aim: This critique paper is designed to address questions that need to be answered by future scientific studies and to offer guidelines for these studies.Approach: Owing to its proximity for a possible approval in clinical use and short-lasting pharmacokinetics, our focus is predominantly on psilocybin. Psilocybin is allegedly, next to lysergic acid diethylamide (LSD), one of the two most frequently used psychedelics to microdose. Where relevant and available, data for other psychedelic drugs are also mentioned.Conclusion: It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses. To that end, (pre)clinical studies including biological (e.g. heart rate, receptor turnover and occupancy) as well as cognitive (e.g. memory, attention) parameters have to be conducted and will shed light on the potential negative consequences microdosing could have.

Unlocked with Blossom Pro

Research Summary of 'Microdosing psychedelics: More questions than answers? An overview and suggestions for future research'

Study Details

Cited By (54)

Papers in Blossom that reference this study

LSD microdosing in major depressive disorder: results from an open-label trial

Allen, N., Alshakhouri, M., Daldegan-Bueno, D. et al. · Neuropharmacology (2026)

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

Fejer, G., Fiacchino, D., Hommel, B. et al. · Neuropsychopharmacology (2025)

7 cited
Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice

Calderon, J. R., Effinger, D. P., King, J. L. et al. · ACS Pharmacology and Translational Science (2025)

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults A Randomized Clinical Trial

Becker, A. M., de Jesus, N. M. S., Haijen, E. C. H. M. et al. · JAMA Psychiatry (2025)

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use

Beidas, Z., Fewster, E. C., Husain, M. I. et al. · Journal of Psychoactive Drugs (2024)

Expectancy effects in psychedelic trials

Heifets, B. D., Szigeti, B. · Biological Psychiatry (2024)

Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine

de Wit, H., Frohlich, J, Haggarty, C. J., Lee, R. et al. · Neuropsychopharmacology (2024)

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

Bojarski, A. J., Brandt, T. G., Casado-Sainz, A. et al. · Molecular Psychiatry (2023)

Psychedelic Intimacy: Altered States of Consciousness in Romantic Relationships

Anderson, K., Mason, N. L., Neubert, J. J. · Psyarxiv (2023)

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

Bonnelle, V., Cavarra, M., Feilding, A. et al. · European Journal of Pain (2023)

Show all 54 papers
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Holstein, A., Klumpers, L. E., Knowles, R. et al. · Journal of Psychopharmacology (2023)

Microdosing psychedelics has no impact on cognitive function in naturalistic settings

Dinkelacker, J., Pop, I. · Journal of Clinical Psychiatry (2023)

2 cited
The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing

Carhart-Harris, R. L., Erritzoe, D., Nutt, D. J. et al. · Scientific Reports (2023)

21 cited
Unlocking the self: Can microdosing psychedelics make one feel more authentic?

Dinkelacker, J., Pop, I. · Nordic Studies on Alcohol and Drugs (2023)

5 cited
Microdosing psychedelics - Does it have an impact on emodiversity?

Dinkelacker, J., Pop, I. · Journal of Psychedelic Studies (2023)

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial

Baumann, S., Carhart-Harris, R. L., Erritzoe, D. et al. · Psyarxiv (2022)

Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD

Barros-Álvarez, X., Cao, C., Dämgen, M. A. et al. · Neuron (2022)

Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives

Kaypak, A. C., Raz, A. · Transcultural Psychiatry (2022)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., de la Fuente, L. A., Kuchar, M. et al. · Translational Psychiatry (2022)

90 cited
Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

A systematic literature review of clinical trials and therapeutic applications of ibogaine

Dürsteler, K. M., Frölich, K., Köck, P. et al. · Journal of Substance Abuse Treatment (2022)

46 cited
Natural language signatures of psilocybin microdosing

Carrillo, F., Cavanna, F., de la Fuente, L. A. et al. · Psychopharmacology (2022)

11 cited
Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity

Barr, A. M., Honer, W. G., Huang, J. et al. · Frontiers in Psychiatry (2022)

Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

Aday, J. S., Bradley, E. R., Heifets, B. D. et al. · Psychopharmacology (2022)

Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study

Bershad, A. K., Bremmer, M. P., de Wit, H. et al. · Addiction Biology (2022)

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT

Barker, S. A. · Psychopharmacology (2022)

The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 - 2021)

Liknaitzky, P., Polito, V. · Psyarxiv (2021)

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity

Cavanna, F., de la Fuente, L. A., Janeckova, S. et al. · Translational Psychiatry (2021)

5 cited
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

Bourzat, F., Harvey, K., Kryskow, P. et al. · Scientific Reports (2021)

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults

Malina, M., Perry, C. M. · Psychopharmacology (2021)

From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders

Figiel, M., Kozłowska, U., Nichols, C. D. et al. · Journal of Neurochemistry (2021)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Cleary, S., Corrigan, K., Haran, M. et al. · Irish Journal of Medical Science (2021)

Exploring the relationship between microdosing, personality and emotional insight: A prospective study

Bright, S. J., Dressler, H. M., Polito, V. · Journal of Psychedelic Studies (2021)

Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study

Fejer, G., Hajkova, K., Kuchar, M. et al. · Psychopharmacology (2021)

42 cited
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Balaet, M., Buchborn, T., Carhart-Harris, R. L. et al. · Scientific Reports (2021)

112 cited
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects

Olson, D. E. · ACS Pharmacology and Translational Science (2020)

The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

Dolder, P. C., Feilding, A., Holze, F. et al. · European Neuropsychopharmacology (2020)

95 cited
Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Erritzoe, D. et al. · Acta Psychiatrica Scandinavica (2020)

Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects

Borgwardt, S., Holze, F., Lang, U. E. et al. · Frontiers in Psychiatry (2020)

Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Dolder, P. C., Duthaler, U., Feilding, A. et al. · Clinical Pharmacology and Therapeutics (2020)

49 cited
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Borgwardt, S., Dolder, P. C., Duthaler, U. et al. · Neuropsychopharmacology (2020)

192 cited
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review

Bouso, J. C., Ona, G. · Neuroscience and Biobehavioral Reviews (2020)

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

Dolder, P. C., Eckert, A., Feilding, A. et al. · ACS Pharmacology and Translational Science (2020)

The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan

Carbonaro, T. M., Griffiths, R. R., Johnson, M. W. · Psychopharmacology (2020)

Psychedelic Psychiatry’s Brave New World

Carhart-Harris, R. L., Erritzoe, D., Nutt, D. J. · Cell (2020)

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Anderson, T., Dinh-Williams, L., Hapke, E. et al. · Journal of Psychopharmacology (2020)

55 cited
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders

Amanda, N., Jungaberle, H., Lea, T. et al. · Psychopharmacology (2020)

65 cited
Microdosing psychedelics: Motivations, subjective effects and harm reduction

Amada, N., Jungaberle, H., Klein, M. et al. · International Journal of Drug Policy (2020)

95 cited
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

Carhart-Harris, R. L., Family, N., Goble, D. J. et al. · Psychopharmacology (2019)

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Dolder, P. C., Hutten, N. P. W., Kuypers, K. P. C. et al. · Frontiers in Psychiatry (2019)

Your Library